NCT01121406 - BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer | Biotech Hunter

Enrollment

110

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions

Ovarian Neoplasms

Interventions

DRUG

Paclitaxel

Patients receive paclitaxel in a 4 week schedule

DRUG

Gemcitabine

Patients receive gemcitabine in a 3 week schedule

DRUG

Topotecan

Patients receive topotecan in 3 or 4 week schedule

DRUG

Pegylated liposomal doxorubicin (PLD)

Patients receive PLD in a 4 week schedule

DRUG

BI 6727

Patients receive BI 6727 infusion every 3 weeks

Trial Locations (31)

Unknown

1230.18.32003 Boehringer Ingelheim Investigational Site, Brussels

1230.18.32004 Boehringer Ingelheim Investigational Site, Edegem

1230.18.32002 Boehringer Ingelheim Investigational Site, Ghent

1230.18.32001 Boehringer Ingelheim Investigational Site, Leuven

1230.18.3321A Boehringer Ingelheim Investigational Site, Angers

1230.18.3307A Boehringer Ingelheim Investigational Site, Bordeaux

1230.18.3301A Boehringer Ingelheim Investigational Site, Caen

1230.18.3322A Boehringer Ingelheim Investigational Site, Lille

1230.18.3313A Boehringer Ingelheim Investigational Site, Lyon

1230.18.3312A Boehringer Ingelheim Investigational Site, Nantes

1230.18.3308A Boehringer Ingelheim Investigational Site, Nice

1230.18.3302A Boehringer Ingelheim Investigational Site, Paris

1230.18.3314A Boehringer Ingelheim Investigational Site, Paris

1230.18.3309A Boehringer Ingelheim Investigational Site, Pierre-Bénite

1230.18.3305A Boehringer Ingelheim Investigational Site, Reims

1230.18.3320A Boehringer Ingelheim Investigational Site, Saint-Brieuc

1230.18.3311A Boehringer Ingelheim Investigational Site, Strasbourg

1230.18.3310A Boehringer Ingelheim Investigational Site, Toulouse

1230.18.3315A Boehringer Ingelheim Investigational Site, Vandœuvre-lès-Nancy

1230.18.42101 Boehringer Ingelheim Investigational Site, Bratislava

1230.18.42103 Boehringer Ingelheim Investigational Site, Poprad

1230.18.34006 Boehringer Ingelheim Investigational Site, Badalona

1230.18.34001 Boehringer Ingelheim Investigational Site, Barcelona

1230.18.34005 Boehringer Ingelheim Investigational Site, Barcelona

1230.18.34007 Boehringer Ingelheim Investigational Site, Girona

1230.18.34004 Boehringer Ingelheim Investigational Site, L'Hospitalet de Llobregat

1230.18.34002 Boehringer Ingelheim Investigational Site, Madrid

1230.18.34003 Boehringer Ingelheim Investigational Site, Madrid

1230.18.46005 Boehringer Ingelheim Investigational Site, Linköping

1230.18.46001 Boehringer Ingelheim Investigational Site, Stockholm

1230.18.46003 Boehringer Ingelheim Investigational Site, Uppsala